Samsung Biologics holds 11th Annual General Meeting of Shareholders

[ad_1]

INCHEON, South Korea, March 28, 2022 /PRNewswire/ — Samsung Biologics (KRX: 207940.KS), the world’s main deal improvement and manufacturing firm (CDMO), hosted its 11^th Once-a-year Common Assembly of Shareholders (AGM) currently. 5 matters had been introduced and approved unanimously at this year’s assembly, which provided the approval of monetary statement, appointment of administrators, appointment of director as audit committee member, appointment of audit committee member, and acceptance of the remuneration limit for the administrators.

CEO John Rim at the 11th Annual General Meeting of Shareholders — CEO John Rim at the 11th Once-a-year Standard Meeting of Shareholders

“As component of our vision, we are now venturing into the a few core pillars of our multidimensional expansion strategy, encompassing expanded producing potential, ongoing advancements in small business portfolio, and bigger global footprint,” said John Rim, CEO of Samsung Biologics in an deal with to the shareholders. “As a major CDMO provider company, we will proceed to reveal our excellent business operations in the course of our benefit chains to in the long run contribute to conserving the lives of patients and construct a better potential for all.”

Very same as previous calendar year, Samsung Biologics implemented an digital voting procedure, and the assembly was built available for virtual participation by way of a stay broadcast. Because of to the ongoing COVID-19 pandemic, the enterprise took precautionary actions throughout the conference to make certain the overall health and safety of all attendees.

Samsung Biologics’ Plant 4 is at the moment underneath steady construction to start functions by the stop of this calendar year, and the company is steadily securing pre-revenue with shoppers. Upon the total completion of Plant 4 in 2023, the organization is predicted to keep the world’s premier biomanufacturing capability. The corporation is even further seeking into securing more internet sites inside of Songdo for its next bio campus, and also overseas in multiple areas to broaden its business enterprise in closer proximity to its world-wide consumers.

For much more specifics of the 2022 AGM, make sure you see the reference content obtainable below the following hyperlink.

About Samsung Biologics Co., Ltd.

Samsung Biologics (KRX: 207940.KS) is a completely integrated CDMO supplying point out-of-the-art deal development, production, and laboratory screening expert services. With tested regulatory approvals, the biggest capability, and the quickest throughput, Samsung Biologics is an award-winning lover of alternative and is uniquely capable to support the improvement and manufacturing of biologics goods at each individual phase of the course of action while conference the evolving requirements of biopharmaceutical corporations around the world. For much more info, stop by samsungbiologics.com.

Media Make contact with
Claire Kim
Senior Director
World-wide Advertising and marketing Communication Crew
Samsung Biologics
[email protected]